A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy. Using an AI-driven robotics laboratory , the team identified INS018_055 (Rentosertib) —a potent small-molecule TNIK previously developed by Insilico Medicine, which has already advanced into clinical trials for idiopathic pulmonary fibrosis (IPF)—as a highly effective senomorphic agent capable of mitigating cellular senescence. The findings were published in Aging and Disease （IF=7.843).
"Generative AI has already showcased extraordinary potential in transforming healthcare and advancing longevity research," said Qiuqiong Tang, PhD, biologist at Insilico Medicine and first author of the paper. "This study exemplifies how AI can uncover dual-purpose therapeutic opportunities, addressing both disease-specific indications like IPF and broader systemic biological aging processes. Additionally, it underscores the powerful capabilities of our robotics lab in validating preclinical experiments with unprecedented efficiency, reproducibility, and unbiased analyses."
Previous studies have shown that TNIK (Traf2- and Nck-interacting kinase) plays an essential role in the cellular senescence process by orchestrating key signaling pathways tightly linked to both cell senescence and fibrosis. In this recent publication, the researchers assessed the potential of Rentosertib as a senomorphic agent by employing a comprehensive approach that combined in vitro senescence models , multi-omics data analysis, and mechanistic evaluations.
Notably the study was conducted exclusively in Insilico's state-of-art, AI-driven robotics laboratory, leveraging advanced AI-agent workflow across multiple stages, including sample processing and quality control, high-throughput screening, imaging, next-generation sequencing, and AI-powered analysis. The AI-agent workflow not only enhances efficiency but also ensures consistent, reproducible results while minimizing biases commonly associated with manual handling. Furthermore, it enables the creation of a dynamic feedback loop, where experimental outcomes continuously refine AI models, thereby improving further precision of target discovery and indication prediction.
The result demonstrates that Rentosertib significantly reduces aging-related markers such as the senescence-associated secretory phenotype (SASP) and extracellular matrix remodeling in various senescence models. Mechanistically, the study reveals that TNIK inhibition alleviates TGF-β and Wnt signaling, pathways strongly implicated in senescence, fibrosis, and aging. Impressively, Rentosertib as a potential senomorphic drug showcased safe and robust senescence attenuation while preserving healthy cell viability.This study paves the way for further exploration of Rentosertib in broader indications,especially in idiopathic aging-related degenerative conditions.
As of the paper's publication, Rentosertib is undergoing a Phase 2 clinical trial in the U.S. and has successfully completed a Phase 2a trial in China, delivering promising results in improving lung function in patients with idiopathic pulmonary fibrosis (IPF) . The development of Rentosertib was enabled by Insilico's proprietary AI platform, which played a key role in identifying its therapeutic target and designing the molecule. This process was detailed in a March 2024 Nature Biotechnology paper, which highlighted the identification of TNIK as a novel therapeutic target for IPF and the subsequent design of Rentosertib.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research.
Powered by Pharma.AI, Insilico has nominated 22 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of over 30 assets since 2021, received IND clearance for 10 molecules, and completed multiple human clinical trials for two of the most advanced pipelines, with positive results announced.
By integrating the technologies of AI and automation, Insilico has demonstrated significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program, and the success rate from DC stage to IND-enabling stage reaches 100%.
Reference
[1] Tang, Q.,et al. (2025) AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent. Aging and disease. doi.org/10.14336/AD.2024.1492
[2] Pun FW., et al. (2022) Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine. Aging. doi.org/10.18632/aging.203960
[3] Ren, F., et al. (2024) A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology. doi.org/10.1038/s41587-024-02143-0
About Insilico's Robotics Lab
Fully operational by the end of 2022, Insilico's robotics lab is a cutting-edge facility featuring 6 automated functional islands seamlessly connected by Insilico's proprietary AI platform and automated guided vehicles. It supports a broad spectrum of tasks, including gene editing, high-throughput screening, high-content imaging, and multi-omics sequencing. Through its seamless integration with Insilico's Pharma.AI platform, the lab accelerates early-stage drug development by enabling efficient target validation, streamlining hits-to-lead molecular discovery, identifying of PCC molecules, and advancing translational medical research such as indication expansion, combination drug testing, MOA and biomarker validation, etc.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
